# A Study of the ILB-3101 in Patients with Advanced Solid Tumors

> **NCT06426680** · PHASE1 · RECRUITING · sponsor: **Innolake Biopharm** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** ILB-3101

## Key facts

- **NCT ID:** NCT06426680
- **Lead sponsor:** Innolake Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-12
- **Final completion:** 2026-03
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06426680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06426680, "A Study of the ILB-3101 in Patients with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06426680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*